Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Comparison of Pharmacokinetics, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in a Randomized, Double-blind, Parallel Controlled, Single-dose Study in Healthy Chinese Male Subjects

NCT07246252 is registered in ClinicalTrials.gov with Taizhou Mabtech Pharmaceutical Co.,Ltd as lead sponsor.

NCT NCT07246252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07246252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Comparison of Pharmacokinetics, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in a Randomized, Double-blind, Parallel Controlled, Single-dose Study in Healthy Chinese Male Subjects
Lead sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase
Phase 1
Overall status
Completed
Start date
March 28, 2024
Completion date
December 2, 2024
Enrollment
114 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers (hv)